A clear, referenced overview of tirzepatide, the peptide that acts on both the GIP and GLP-1 receptors, for students, researchers and readers who want the facts behind the headlines.
Tirzepatide is a synthetic peptide that activates two receptors at once: the receptor for GIP (glucose-dependent insulinotropic polypeptide) and the receptor for GLP-1 (glucagon-like peptide-1). Both hormones are released by the gut after a meal and help control blood sugar and appetite. Older medicines such as liraglutide and semaglutide act on the GLP-1 receptor only.
In large trials, tirzepatide lowered average blood sugar more than several established diabetes treatments. In adults with obesity, the highest dose reduced body weight by about 21% on average over 72 weeks. Those results turned it into one of the most studied metabolic drugs of the decade.
This site explains how the molecule works, what each major trial measured, how it came to be approved, and why the licensed medicine and research-grade peptide are treated so differently. Figures come from peer-reviewed papers, and the trial page lists them.
Tirzepatide.cfd offers general information and does not give medical advice. Decisions about treatment belong with a doctor who knows your medical history. Research-grade tirzepatide is sold for laboratory work only and is not meant for use in people.
| Research code | LY3298176 |
| Compound type | Synthetic peptide of 39 amino acids with a C20 fatty diacid side chain |
| Targets | GIP receptor and GLP-1 receptor |
| Developer | Eli Lilly and Company (Indianapolis, USA) |
| Half-life | About 5 days, allowing one injection per week |
| Brand names | Mounjaro (type 2 diabetes and weight management); Zepbound (US, weight management and sleep apnoea) |
| Legal status | Prescription-only medicine in the EU, UK, US and many other countries |